K. Klingman

发表

Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

C. Fichtenbaum, K. Robertson, B. Taiwo, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD4+ count-guided interruption of antiretroviral treatment.

J Darbyshire, N Clumeck, J Hoy, 2006, The New England journal of medicine.

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

P. Douglas, E. Gardner, Kathleen V Fitch, 2020, The Journal of infectious diseases.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

R. Haubrich, D. Havlir, J. Mellors, 2009, AIDS.

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

J. Mellors, A. Collier, E. Acosta, 2005, AIDS.

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers

J. Park, C. Flexner, C. Hendrix, 2008, Antimicrobial Agents and Chemotherapy.

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

Examining the challenges and solutions to the implementation of trials in resource-limited settings: Limited Resource Trials.

J. Hitti, K. Klingman, D. McMahon, 2012, Applied clinical trials.

Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188

J. Park, F. Aweeka, S. Cohn, 2010, Journal of acquired immune deficiency syndromes.

Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race–ethnicity determine the degree of regimen complexity

R. Haubrich, K. Tashima, V. Johnson, 2015, HIV clinical trials.

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

B. Chi, D. Moodley, L. Mofenson, 2016, The New England journal of medicine.

Dynamics of respiratory tract colonization by Branhamella catarrhalis in bronchiectasis.

S. Hill, T. Murphy, K. Klingman, 1995, American journal of respiratory and critical care medicine.

Purification and characterization of a high-molecular-weight outer membrane protein of Moraxella (Branhamella) catarrhalis

T. Murphy, K. Klingman, 1994, Infection and immunity.

Depot Medroxyprogesterone Acetate in Combination with a Twice-Daily Lopinavir-Ritonavir-Based Regimen in HIV-Infected Women Showed Effective Contraception and a Lack of Clinically Significant Interactions, with Good Safety and Tolerability: Results of the ACTG 5283 Study

J. Park, F. Aweeka, S. Cohn, 2015, Antimicrobial Agents and Chemotherapy.

A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy

D. Moisi, J. Berger, D. Kitch, 2017, Open forum infectious diseases.

Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir

C. Fichtenbaum, B. Taiwo, T. Brown, 2016, AIDS.

Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial

B. Chi, D. Moodley, G. Theron, 2022, BMC Infectious Diseases.

Genetic Diversity among Strains of Moraxella catarrhalis: Analysis Using Multiple DNA Probes and a Single-Locus PCR-Restriction Fragment Length Polymorphism Method

J. Kalbfleisch, G. Ehrlich, K. Klingman, 1998, Journal of Clinical Microbiology.

Airway inflammation and etiology of acute exacerbations of chronic bronchitis.

B. Grant, T. Murphy, S. Sethi, 2000, Chest.

Simultaneous respiratory tract colonization by multiple strains of nontypeable haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy.

T. Murphy, S. Sethi, G. Doern, 1999, The Journal of infectious diseases.

Immune Responses to Specific Antigens of Streptococcus pneumoniae and Moraxella catarrhalis in the Respiratory Tract

N. Yamanaka, K. Klingman, S. Hollingshead, 2000, Infection and Immunity.

Phage Antibodies Obtained by Competitive Selection on Complement-Resistant Moraxella (Branhamella)catarrhalis Recognize the High-Molecular-Weight Outer Membrane Protein

T. Logtenberg, J. de Kruif, K. Klingman, 1998, Infection and Immunity.

Protein High-Molecular-Weight Outer Membrane Recognize the catarrhalis ) Branhamella ( Moraxella Selection on Complement-Resistant Phage Antibodies Obtained by Competitive

T. Logtenberg, K. Klingman, H. Bootsma, 1997 .

Infant Outcomes After Maternal Antiretroviral Exposure in Resource-Limited Settings

L. Mofenson, J. Currier, J. Hitti, 2012, Pediatrics.

A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy

C. Fichtenbaum, J. Brenchley, D. Kitch, 2021, Open forum infectious diseases.

Screening and Enrollment by Sex in HIV Clinical Trials in the United States.

A. Collier, S. Koletar, L. Smeaton, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study

C. Dykes, L. Demeter, K. Klingman, 2011, HIV clinical trials.

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients

L. Bacheler, Hongyu Jiang, C. Dykes, 2009, AIDS.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial.

Michael T. Lu, P. Douglas, U. Lalloo, 2020, The Journal of infectious diseases.

HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors

R. Haubrich, K. Tashima, V. Johnson, 2015, Annals of Internal Medicine.

Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).

M. Lederman, R. Bosch, J. Lake, 2017, Journal of clinical lipidology.

Diagnosis, epidemiology and pathogenesis of bacterial infections in the molecular era

T. Murphy, S. Sethi, K. Klingman, 1996, Clinical molecular pathology.

Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.

V. Johnson, M. Saag, E. Acosta, 2019, AIDS research and human retroviruses.

Women have enhance d bone loss associated with phosphaturia and CD 4 R cell restoration during initial antiretroviral therapy

S. Cremers, C. Fichtenbaum, B. Taiwo, 2018 .

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

H. Lane, D. Cooper, A. Phillips, 2015, The New England journal of medicine.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2004, The New England journal of medicine.

Hepatotoxicity and Liver-Related Mortality in Women of Child-Bearing Potential Living With HIV and High CD4 Counts Initiating Efavirenz-Containing Regimens.

J. Currier, M. Fowler, T. Chipato, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.

M. Hughes, J. Mellors, J. Hitti, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Class-sparing regimens for initial treatment of HIV-1 infection.

Lynne Peeples, Richard Haubrich, Susan Swindells, 2008, The New England journal of medicine.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2006, JAMA.

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women

I. Frank, K. Mayer, C. Hendrix, 2017, Annals of Internal Medicine.

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

I. Frank, K. Mayer, C. Hendrix, 2016, The Journal of infectious diseases.

Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared to men.

R. Bosch, J. Currier, M. Fowler, 2019, AIDS.

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial

D. Cooper, A. Phillips, J. Lundgren, 2017, The lancet. HIV.

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

D. Katzenstein, J. Crump, J. Bartlett, 2012, AIDS.

LB2305. Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial

J. Lundgren, J. Neaton, B. Grund, 2022, Open Forum Infectious Diseases.

Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial

B. Chi, D. Moodley, G. Theron, 2018, HIV clinical trials.

Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3

L. Mofenson, L. Aurpibul, J. Currier, 2017, PloS one.

Adverse Pregnancy Outcomes Among Women Who Conceive on Antiretroviral Therapy

S. Spector, L. Aurpibul, J. Currier, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial

C. Katlama, D. Cooper, B. Grund, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low rate of sex-specific analyses in presentations at the Conference of Retroviruses and Opportunistic Infections (CROI) meeting, 2018: Room to improve.

S. Gianella, E. Scully, E. Connick, 2019, Journal of acquired immune deficiency syndromes.

Quality of Life Among Individuals with HIV Starting Antiretroviral Therapy in Diverse Resource-Limited Areas of the World

T. Flanigan, D. Celentano, L. Smeaton, 2012, AIDS and Behavior.

Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV

J. Mellors, A. Collier, K. Klingman, 2008, HIV clinical trials.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

D. Kuritzkes, K. Squires, B. Schackman, 2007, AIDS.

Nearest neighbor analysis of outer membrane proteins of nontypeable Haemophilus influenzae

T. Murphy, K. Klingman, E. Jansen, 1988, Infection and immunity.

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

J. Park, C. Flexner, C. Hendrix, 2007, Antimicrobial Agents and Chemotherapy.

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

D. Katzenstein, J. Crump, J. Bartlett, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR 4 Antagonist AMD 070 in Healthy Volunteers †

J. Park, C. Flexner, C. Hendrix, 2008 .

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers (cid:1) †

J. Park, C. Flexner, C. Hendrix, 2008 .

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection

R. Haubrich, D. Havlir, J. Mellors, 2011, AIDS.

Sex-Associated Differences in Pre-Antiretroviral Therapy Plasma HIV-1 RNA in Diverse Areas of the World Vary by CD4+ T-Cell Count

T. Flanigan, J. Currier, L. Smeaton, 2011, Antiviral therapy.

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

A. Rancourt, C. Fichtenbaum, P. Douglas, 2020, HIV research & clinical practice.

Addressing Standards of Care in Resource-Limited Settings

J. Marrazzo, K. Klingman, L. Dawson, 2014, Journal of acquired immune deficiency syndromes.

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.

R. Paredes, H. Furrer, A. Phillips, 2023, NEJM evidence.

Genetics of Bacteria: Role in Pathogenesis of Infection of the Respiratory Tract

T. Murphy, K. Klingman, 1999 .

Increased risk of suicidal behaviour with use of efavirenz: results from the START trial

C. Katlama, D. Cooper, B. Grund, 2016 .

M. Lederman, R. Bosch, J. Lake, 2017, Journal of clinical lipidology.

Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207

J. Mellors, U. Lalloo, J. Pape, 2014, Journal of AIDS & clinical research.

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

D. Kuritzkes, K. Squires, C. Shikuma, 2007, The Journal of infectious diseases.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

R. Haubrich, D. Havlir, J. Mellors, 2009, AIDS.

Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir

C. Fichtenbaum, T. Brown, A. Landay, 2016, AIDS.